NASDAQ:AXNX
Axonics Modulation Technologies Inc. Stock News
$67.57
+0.250 (+0.371%)
At Close: Jun 21, 2024
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank
05:01am, Monday, 20'th May 2024
Amalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities an
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
04:01pm, Thursday, 16'th May 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™
Axonics Reports First Quarter 2024 Financial Results
04:01pm, Tuesday, 30'th Apr 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfu
Boston Scientific Announces Results for First Quarter 2024
06:30am, Wednesday, 24'th Apr 2024
MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
07:54am, Thursday, 04'th Apr 2024
Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
01:01pm, Friday, 29'th Mar 2024
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axonics Stockholders Approve Merger Agreement with Boston Scientific
04:01pm, Friday, 22'nd Mar 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord
Axonics Provides Update on Inter Partes Review Proceedings
04:54pm, Thursday, 21'st Mar 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
09:56am, Friday, 15'th Mar 2024
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
06:00am, Thursday, 14'th Mar 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunct
Axonics Responds to ITC Action by Medtronic
04:01pm, Thursday, 29'th Feb 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received notice that Medtronic has filed a complaint with the U.S. International Trade Commission (ITC), along
Axonics Modulation Technologies (AXNX) Q4 Earnings and Revenues Surpass Estimates
06:41pm, Wednesday, 28'th Feb 2024
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc
4 Stocks Backed by High Efficiency to Enrich Your Portfolio
09:05am, Wednesday, 31'st Jan 2024
Invest in companies like Axonics (AXNX), Enerpac Tool Group (EPAC), Cardinal Health (CAH) and Acuity Brands (AYI) due to higher efficiency levels.
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
06:30am, Wednesday, 31'st Jan 2024
MARLBOROUGH, Mass. , Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reporte